Reviva Pharma announces 1:20 reverse stock split to regain Nasdaq minimum bid price compliance

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reverse stock split at 1:20 ratio effective 12:01 a.m. ET on March 9, 2026; no fractional shares, rounding up.
Nasdaq Staff granted an exception to demonstrate compliance with $1 bid price requirement through March 27, 2026.
Company received delisting notice in Nov 2025; hearing held Jan 8, 2026; exception granted.
If compliance not regained, stock may be delisted, harming liquidity and capital access.
CUSIP changes to 76152G 209; trading symbol remains RVPH.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC.: Filing of Certificate of Amendment to effect a one-for-twenty reverse stock split (effective 2026-03-09).

Change: charter amendment
Effective: 2026-03-09

Exact text from the filing

filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-006991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.